Tetracosactide depot - Slan Medicinal Holdings

Drug Profile

Tetracosactide depot - Slan Medicinal Holdings

Alternative Names: Cosyntropin depot - Slán Medicinal Holdings; Synthetic ACTH Depot - Slán Medicinal Holdings

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer Mallinckrodt Inc.; Slan Medicinal Holdings
  • Class Anti-inflammatories; Corticosteroids; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Adrenal gland disorders
  • Preclinical Infantile spasms

Most Recent Events

  • 07 Nov 2017 Tetracosactide depot licensed to Depomed in USA
  • 07 Nov 2017 Clinical trials in Adrenal gland disorders in USA (Parenteral) before November 2017
  • 07 Nov 2017 Preclinical trials in Infantile spasms in USA (Parenteral) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top